DXR earnings

Strong Start to 2025 with Unaudited Revenue Increases Leading to Cash Flow Positive Operating Company Results Oak Ridge, TN, March 04, 2025 (GLOBE NEWSWIRE) -- Daxor Corporation (NASDAQ:DXR), the global leader in blood volume measurement technology, announces today the filing of its Annual Report to Shareholders on Form N-CSR, disclosing its schedule of portfolio holdings as of December 31, 2024. Management reported a NAV of $7.25 per share for fiscal 2024 versus $7.08 for the comparable period in 2023. The company has reported a successful 2024 and an even stronger start to 2025, driven by a series of strategic advancements in product development, revenue growth, and key acquisitions. D

Oak Ridge, TN, March 04, 2025 (GLOBE NEWSWIRE) -- Daxor Corporation (NASDAQ:DXR), the global leader in blood volume measurement technology, today announces it will host an investor conference call on Thursday, March 6, 2025, at 4:30 p.m. ET. President and CEO Michael Feldschuh and CFO Robert Michel will review financial results and provide an update on corporate developments. After Management's presentation, there will be an opportunity for Q&A. Investors are encouraged to submit questions in advance via email to: info@daxor.com. To participate, register HERE. A webcast replay of the call will be available on the Company's website at Daxor.com. About Daxor Corporation Daxor Corporatio

Strong Start to 2025 with Unaudited Revenue Increases Leading to Cash Flow Positive Operating Company Results Oak Ridge, TN, March 04, 2025 (GLOBE NEWSWIRE) -- Daxor Corporation (NASDAQ:DXR), the global leader in blood volume measurement technology, announces today the filing of its Annual Report to Shareholders on Form N-CSR, disclosing its schedule of portfolio holdings as of December 31, 2024. Management reported a NAV of $7.25 per share for fiscal 2023 versus $7.08 for the comparable period in 2023. The company has reported a successful 2024 and an even stronger start to 2025, driven by a series of strategic advancements in product development, revenue growth, and key acquisitions. D

Conference Call to be held today at 9:00 AM EST Oak Ridge, TN, March 02, 2023 (GLOBE NEWSWIRE) -- Daxor Corporation (NASDAQ:DXR), the global leader in blood volume measurement technology, filed its Annual Report to Shareholders on Form N-CSR on March 1, 2023, disclosing its schedule of portfolio holdings as of December 31, 2022. Management reported a NAV of $6.75 per share for fiscal 2022 versus $5.24 for the comparable period in 2021, a $1.51 increase or 36.95%, as well as a 20.5% increase in unaudited revenues and sales for its operating division, which produces and distributes its blood volume analysis (BVA) diagnostic systems and single use test kits which rose by 59.5%. "We a

Conference Call to be held at 9 AM EST March 2, 2023 Oak Ridge, TN, March 01, 2023 (GLOBE NEWSWIRE) -- Daxor Corporation (NASDAQ:DXR), the global leader in blood volume measurement technology, will report financial results for the full year ending December 31, 2022 on Wednesday, March 1, 2023 after the stock market close, and host a conference call on Thursday, March 2, 2023 at approximately 9:00 a.m. EST. President and CEO Michael Feldschuh and CFO Robert Michel will also host a conference call at 9:00 a.m. EST on Thursday, March 2, 2023 to review financial results and provide an update on corporate developments. Following management's formal remarks, there will be a question-and-answe

Conference Call to be held today at 4:30 p.m. Eastern Time Oak Ridge, TN, Aug. 25, 2022 (GLOBE NEWSWIRE) -- Daxor Corporation (NYSE:DXR), the global leader in blood volume measurement technology, announces today it filed Form N-CSR disclosing its schedule of portfolio holdings for the six months ended June 30, 2022. The increase in revenue of 92.6 percent in the Company's operating division represents strong strides in the commercialization of its BVA-100® Blood Volume Analyzer through a combination of the purchase and leasing of capital equipment, reference lab use, and the opening of twelve new commercial and academic accounts, along with a 9.2 percent price increase that was well rece

Conference Call to be held on the same day at 4:30 p.m. Eastern Time Oak Ridge, TN, Aug. 24, 2022 (GLOBE NEWSWIRE) -- Daxor Corporation (NASDAQ:DXR), the global leader in blood volume measurement technology, will report financial results for the six months ending June 30, 2022, on Thursday, August 25, 2022 at approximately 4:00 p.m. Eastern Time. President and CEO President Michael Feldschuh and CFO Robert Michel will also host an earnings conference call at 4:30 p.m. ET on Thursday, August 25, 2022, to review financial results and provide an update on corporate developments. Following management's formal remarks, there will be a question-and- answer session. Investors are invited to sub